ArticleRSC advances2024
Identification of taurine biomarker in human biofluids using plasmonic patterns of silver nanostructure.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taurine is now widely used as a new biomarker for cardiovascular and neurodegenerative diseases. This study discusses the importance of accurately determining taurine biomarker levels in various tissues and fluids for the early diagnosis of important pathologies and diseases. Current methods for taurine analysis face challenges such as low sensitivity, lack of selectivity, and complex procedures. Therefore, an efficient analytical method/technique is urgently needed by clinicians. A new paper-based photochemical method using triangular silver nanoparticles (TA-AgNPs) as optical nanoprobes was developed to detect taurine in human blood plasma and urine samples. This method involves a chemical reaction between taurine and TA-AgNPs, leading to a color change at pH 4.8, which is detected using a paper-based colorimetry (PCD) assay. The reaction is further confirmed by UV-visible spectrophotometry as the interaction between taurine and TA-AgNPs causes a significant change in the absorption spectrum, enabling the rapid and reliable measurement of this important biomarker with a detection limit of less than 0.2 μM to 20 mM. The method has been successfully applied to bioanalyzing taurine in human body fluids. Additionally, it requires optimized single-drop paper/parafilm-based colorimetric devices (OD-PCDs) for
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.